The treatment of portal hypertension: A meta-analytic review

Gennaro D’Amico, Luigi Pagliaro(Ospedale Vincenzo Cervello), Jaime Bosch(Universitat de Barcelona)
Hepatology
July 1, 1995
10.1002/hep.1840220145
Cited by 1,028Open Access
Full Text

Abstract

Portal hypertension is a major complication of chronic liver disease. Its main clinical consequence, bleeding from ruptured esophagogastric varices, represents a dramatic medical emergency, with mortality rate ranging from 30% to 50%, and is one of the leading causes of death in patients with cirrhosis.'-'

Related Papers

Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
Roberto J. Groszmann, Jackie Bosch, Norman D. Grace et al.|Gastroenterology|1990|727
FAILURE OF REPEATED INJECTION SCLEROTHERAPY TO IMPROVE LONG-TERM SURVIVAL AFTER OESOPHAGEAL VARICEAL BLEEDING
J Terblanche, Delawir Kahn, JohnA.H. Campbell et al.|The Lancet|1983|319
Definitions, methodology and therapeutic strategies in portal hypertension
Roberto de Franchis, Jean‐Pierre Pascal, Ermanno Ancona et al.|Journal of Hepatology|1992|287
Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding
Andrew K. Burroughs, P. Aiden McCormick, Michael D. Hughes et al.|Gastroenterology|1990|248
A clinical investigation of the portacaval shunt
Francis C. Jackson, Edward B. Perrin, A. Gordon Smith et al.|The American Journal of Surgery|1968|230